Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma

BackgroundImmune checkpoint inhibitors (ICIs) have been transformative in the treatment of patients with metastatic melanoma, but primary and secondary resistance to ICI treatment is common. One key mechanism for ICI resistance is the skewing of the immune response from a cytotoxic (Th1) to a chroni...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuan Yao, Yiyi Yan, Vera J. Suman, Allan B. Dietz, Courtney L. Erskine, Anastasios Dimou, Svetomir N. Markovic, Robert R. McWilliams, Heather N. Montane, Matthew S. Block
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
melanoma
ibrutinib
pembrolizumab
Th2 (type-2) immune responses
Th1 immune responses
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1491448/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1491448/full

Similar Items